VitaSpring Biomedical Co. Ltd. (VSBC) stock
Close on Oct 19, 2026Market cap $6.58MP/E –Yield –
VitaSpring Biomedical Co. Ltd. reported revenue of $0 for the twelve months to Jul 31, 2026. At the latest close the market valued the company at $6.58M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026
Valuation
- Market cap
- $6.58M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$455.64K
- EPS, diluted
- $0.00
- Book value per share
- -$0.02
- Diluted shares
- 207M
Trading
- Previous close
- $0.03
- Open
- $0.03
- Day's range
- $0.03 – $0.03
- Volume
- 0
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | VSBC | S&P 500 | Difference | VSBC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +186.5% | +0.6% | +185.9 pts | ||
| 3 months | +186.5% | +3.4% | +183.1 pts | ||
| Year to date | -96.8% | +13.3% | −110.1 pts | ||
| 1 year | -96.8% | +16.6% | −113.4 pts | ||
| 3 years | -99.8% | +86.4% | −186.2 pts | -87.4% | +23.1% |
| 5 years | -99.8% | +81.9% | −181.6 pts | -71.0% | +12.7% |
Ten years at a glance
Fiscal years 2017 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
About VitaSpring Biomedical
Services-Commercial Physical & Biological Research
VitaSpring Biomedical Co. Ltd. is a development-stage biomedical company dedicated to researching, developing, and commercializing technologies that support wellness, regenerative medicine, and healthy lifestyles. The company concentrates on advancing cellular medical solutions utilizing its proprietary X.msc mesenchymal stem-cell platform and derivative exosome formulations. These technologies are intended for potential applications in tissue repair, skincare, preventive healthcare, and anti-aging. VitaSpring does not currently sell consumer products or therapies, as its offerings remain in early development and require scientific evaluation alongside regulatory clearances. Operating under a business-to-business model, the firm intends to serve institutional and clinical clients through contract cell manufacturing, technology licensing, and research collaborations.
Company profile, executives and historyVitaSpring Biomedical stock: common questions
What is VitaSpring Biomedical's stock price?
VSBC closed at $0.03 on Oct 19, 2026, up 0.00% on the day.
What is VitaSpring Biomedical's market cap?
VitaSpring Biomedical was worth $6.58M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is VSBC's P/E ratio?
VitaSpring Biomedical lost money over the twelve months to Jul 31, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does VitaSpring Biomedical make?
VitaSpring Biomedical reported revenue of $0 for the twelve months to Jul 31, 2026.
Does VitaSpring Biomedical pay a dividend?
No. VitaSpring Biomedical has not paid a cash dividend over the last twelve months.
How has VSBC stock performed over the past year?
Including dividends, VSBC returned -96.8% over the past year, against +16.6% for the S&P 500.
Who are VitaSpring Biomedical's competitors?
Companies most similar to VitaSpring Biomedical by business, industry and size include MXCT, IBAC, BUDZ, ONMD, FOXO.
See a number that looks wrong?